Insulin glargine and lixisenatide Subcutaneous and SymPak II
Determining the interaction of Insulin glargine and lixisenatide Subcutaneous and SymPak II and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin glargine / lixisenatide
Brand name: Soliqua 100/33
Synonyms: Insulin glargine and lixisenatide (Subcutaneous)
Generic Name: brompheniramine / chlorpheniramine / methscopolamine / phenylephrine / pseudoephedrine
Brand name: SymPak II
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin glargine and lixisenatide Subcutaneous-Sympazan
- Insulin glargine and lixisenatide Subcutaneous-Symproic
- Insulin glargine and lixisenatide Subcutaneous-Symtuza
- Insulin glargine and lixisenatide Subcutaneous-Synalar
- Insulin glargine and lixisenatide Subcutaneous-Synalar (Fluocinolone Cream and Ointment)
- Insulin glargine and lixisenatide Subcutaneous-Synalar (Fluocinolone Solution)
- SymPak II-Insulin glargine, recombinant Subcutaneous
- SymPak II-Insulin glulisine
- SymPak II-Insulin Glulisine (Cartridges and Pens)
- SymPak II-Insulin Glulisine (Vials)
- SymPak II-Insulin glulisine Subcutaneous
- SymPak II-Insulin human inhaled Inhalation